Cargando…
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing unexpected durable responses in an expanding list of advanced disease indications...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048671/ https://www.ncbi.nlm.nih.gov/pubmed/30034550 http://dx.doi.org/10.1177/1758835918786228 |
_version_ | 1783340135918600192 |
---|---|
author | Flynn, Michael Young, Kate Cunningham, David Starling, Naureen |
author_facet | Flynn, Michael Young, Kate Cunningham, David Starling, Naureen |
author_sort | Flynn, Michael |
collection | PubMed |
description | Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing unexpected durable responses in an expanding list of advanced disease indications. Although OG cancers have traditionally been considered to be more challenging to treat with immunotherapy than some other malignancies because of their variable tumour mutational burden and relative scarcity of infiltrating T cells, immune checkpoint inhibitor (ICPI) trials conducted over the last few years suggest there is an important role for these treatments. ICPI efficacy may be demonstrated in specific molecular subtypes of OG cancer. This review outlines the improvements in defining predictive biomarkers of responsiveness to ICPIs. Increasingly, identification of an expanding list of ICPI resistance mechanisms will drive biomarker-directed research. In addition, the specific rationale to combine ICPIs with chemotherapies, radiotherapies, targeted therapies and other novel immunotherapeutic drugs will be discussed. |
format | Online Article Text |
id | pubmed-6048671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60486712018-07-20 The evolving immunotherapeutic landscape in advanced oesophagogastric cancer Flynn, Michael Young, Kate Cunningham, David Starling, Naureen Ther Adv Med Oncol Review Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing unexpected durable responses in an expanding list of advanced disease indications. Although OG cancers have traditionally been considered to be more challenging to treat with immunotherapy than some other malignancies because of their variable tumour mutational burden and relative scarcity of infiltrating T cells, immune checkpoint inhibitor (ICPI) trials conducted over the last few years suggest there is an important role for these treatments. ICPI efficacy may be demonstrated in specific molecular subtypes of OG cancer. This review outlines the improvements in defining predictive biomarkers of responsiveness to ICPIs. Increasingly, identification of an expanding list of ICPI resistance mechanisms will drive biomarker-directed research. In addition, the specific rationale to combine ICPIs with chemotherapies, radiotherapies, targeted therapies and other novel immunotherapeutic drugs will be discussed. SAGE Publications 2018-07-11 /pmc/articles/PMC6048671/ /pubmed/30034550 http://dx.doi.org/10.1177/1758835918786228 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Flynn, Michael Young, Kate Cunningham, David Starling, Naureen The evolving immunotherapeutic landscape in advanced oesophagogastric cancer |
title | The evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
title_full | The evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
title_fullStr | The evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
title_full_unstemmed | The evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
title_short | The evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
title_sort | evolving immunotherapeutic landscape in advanced oesophagogastric
cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048671/ https://www.ncbi.nlm.nih.gov/pubmed/30034550 http://dx.doi.org/10.1177/1758835918786228 |
work_keys_str_mv | AT flynnmichael theevolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT youngkate theevolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT cunninghamdavid theevolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT starlingnaureen theevolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT flynnmichael evolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT youngkate evolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT cunninghamdavid evolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer AT starlingnaureen evolvingimmunotherapeuticlandscapeinadvancedoesophagogastriccancer |